INVESTORS & MEDIA
News Release
Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval
The conference call will include a presentation followed by a Q&A session and will be accessible through an audio webcast at www.regeneron.com and www.sanofi.com, and also via the following telephone numbers:
International: +1 (973) 890 8355
Access code: 92138426
A replay of the conference call and webcast will be archived on the Companies' websites.
About
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, atopic dermatitis and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
About
Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.
Contacts Regeneron: |
|
Media Relations |
Investor Relations |
Ilana Tabak |
|
Tel: + 1 (914) 847-3836 |
Tel: +1 (914) 847-5126 |
Mobile: +1 (914) 450-6677 |
|
Contacts Sanofi: |
|
Media Relations |
Investor Relations |
Ashleigh Koss |
|
Tel: 908-981-8745 |
Tel: +33 (0) 1 53 77 94 69 |
|
|
Carrie Brown |
|
Tel: +1 (908) 981-6486 |
|
Mobile: +1 (908) 247-6006 |
|
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-and-sanofi-to-host-investor-conference-call-to-discuss-dupixent-dupilumab-approval-300430522.html
SOURCE
News Provided by Acquire Media